M
Mark Ashby
Researcher at Genentech
Publications - 19
Citations - 1971
Mark Ashby is an academic researcher from Genentech. The author has contributed to research in topics: Placebo & Tenecteplase. The author has an hindex of 13, co-authored 19 publications receiving 1855 citations. Previous affiliations of Mark Ashby include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antiHistamines, leukotriene receptor antagonists, or both.
Iconographies supplémentaires de l'article : Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H1-antihistamines, leukotriene receptor antagonists, or both.
Journal ArticleDOI
Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
Mark Kozloff,Marianne Ulcickas Yood,Jordan Berlin,Patrick J. Flynn,Fairooz F. Kabbinavar,D. M. Purdie,Mark Ashby,W. Dong,M. M. Sugrue,Axel Grothey +9 more
TL;DR: The observations from the BRiTE study complement and expand upon RCT data, providing clinical information in a large cohort of bevacizumab-treated patients and subgroups such as the elderly.
Journal ArticleDOI
Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
TL;DR: Omalizumab reduces the rate of serious asthma exacerbations and the need for unscheduled outpatient visits, emergency room treatment, and hospitalization in patients with moderate-to-severe allergic asthma.
Journal ArticleDOI
Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer
Saroj Vadhan-Raj,Claire F. Verschraegen,Carlos Bueso-Ramos,Carlos Bueso-Ramos,HE Broxmeyer,Andrzej P. Kudelka,Andrzej P. Kudelka,Ralph S. Freedman,Ralph S. Freedman,Creighton L. Edwards,Creighton L. Edwards,David M. Gershenson,David M. Gershenson,Dennie V. Jones,Dennie V. Jones,Mark Ashby,Mark Ashby,John J. Kavanagh +17 more
TL;DR: A phase I/II trial of recombinant human thrombopoietin (rhTPO, a full-length glycosylated molecule) was evaluated to evaluate the clinical safety and activity of this agent in patients with gynecologic cancer who are at high risk for chemotherapy-induced severeThrombocytopenia.